Allinaire Therapeutics raised $0.7 million to advance its humanized anti-EMAP II monoclonal antibody, a first-in-class disease-modifying therapy in preclinical development for the treatment of pulmonary arterial hypertension, a rare and life-threatening condition causing high blood pressure in the lungs.
